Detalhe da pesquisa
1.
Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Anticancer Drugs
; 18(5): 581-6, 2007 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-17414627
2.
GM1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvant.
J Immunol
; 177(2): 1197-207, 2006 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16818778